ASCO Annual Meeting

Real-world data hint that darolutamide may lengthen time to treatment discontinuation and more, in patients with non-metastatic castration-resistant prostate cancer.

Results from the phase 2b HERIZON-BTC-01 trial presented at ASCO reveal positive efficacy and safety in patient with advanced biliary tract cancer who received zanidatamab.

An update from the phase 3 NAPOLI 3 trial supports the use of NALIRIFOX for the first-line treatment of metastatic pancreatic ductal adenocarcinoma.

According to George Lau, MD, FRCP, FAASLD, patients with unresectable hepatocellular carcinoma who experienced immune-related adverse events with the STRIDE regimen were not precluded from receiving survival benefit.

Phase 3 DUO-O study results reveal a promising strategy for patients with HRD-negative advanced ovarian cancer.

Results from an age group analysis of the monarch E trial reveal continued efficacy and safety with the experimental regimen, abemaciclib plus endocrine therapy.

In a real-world population of patients with relapsed or refractory B-cell acute lymphoblastic leukemia, modest efficacy was demonstrated with brexucabtagene autoleucel.

Phase 2 FELIX study results show 21.3% of the 94 patients infused with obecatagene autoleucel achieved a complete response or complete response with incomplete count recovery.

In a phase 3 study, imetelstat has shown prolonged transfusion independence and hemoglobin increase in the relapsed or refractory myelodysplastic syndrome population.

Manmeet Ahluwalia, MD, discusses results from the CRUX trial which were presented during the 2023 American Society of Clinical Oncology Annual Meeting.

Canadian study results indicate surgical de-escalation is possible in patients with low-risk, early-stage cervical cancer.

Findings presented at a press briefing during the 2023 ASCO Annual Meeting revealed that the primary end point was met in the phase 3 NATALEE trial.

Results from the phase 3 COMMANDS study were presented in a press briefing ahead of the 2023 ASCO Annual Meeting.

Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.

Aaron T. Gerds, MD, MS, discusses the clinical trial development of momelotinib, a JAK1/JAK2 inhibitor that is being investigated for the treatment of patients with myelofibrosis.

The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival.

Rivoceranib showed promising responses in regard to objective response rate and disease control rate when used in patients with recurrent or metastatic adenoid cystic carcinoma.

Dostarlimab monotherapy induced durable antitumor activity in advanced or recurrent endometrial cancer among patients with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease, according to data from 2 expansion cohorts in the GARNET trial.

At the 2022 ASCO Annual Meeting, utilizing matching-adjusted indirect comparison, researchers showed the survival benefit of larotrectinib in patients with TRK fusion-positive tumors.

Selinexor has demonstrated improvement in progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.

Reduced risk of metastatic progression and improved overall survival seen with darolutamide in patients with nonmetastatic castration-resistant prostate cancer.

FOLFOXIRI plus panitumumab should not be recommended as upfront therapy for RAS and BRAF wild-type mCRC patients. according to investigators of the phase 3 TRIPLETE study.

According to Timothy J. Whelan, MD, FASCO, radiotherapy is an inconvenient treatment. It can last daily for up to 5 weeks and it is a costly therapy. Study results shows that is can safely be omitted in the treatment of some patients with luminal A breast cancers.

Phase 3 CAIRO5 showed improvements in progression-free survival and overall response with FOLFOXIRI plus bevacizumab in colorectal cancer liver metastases, but the combination demonstrated a toxic safety profile.

At the 2022 ASCO Annual Meeting, results from the GEMSTONE-302 trial showed that adding sugemalimab to chemotherapy improved survival in patients with metastatic non–small cell lung cancer.

Potential biomarkers of overall survival outcomes have been identified in an exploratory post-hoc analysis of the phase 3 TITAN trial.

According to Conor E. Steuer, MD, patritumab deruxtecan showed promising clinical activity in heavily pretreated patients with advanced non–small cell lung cancer with or without identified variant genomic alterations.

Ruxolitinib and chemotherapy appeared to boost progression-free survival in patients with stage III and IV ovarian cancer when given before or after surgery.

Several key risk factors seen in the monarchE trial of adjuvant abemaciclib could help early monitoring of patients with hormone receptor–positive, HER2-negative, node-positive high-risk early breast cancer to prevent discontinuation.

Dafrafenib plus trametinib demonstrated greatly improved response rates and progression-free survival in pediatric patients with BRAF V600-mutated gliomas.